OBSTETRICS & GYNECOLOGY CONNECT
@OBGynConnect
Followers
2K
Following
33
Media
111
Statuses
248
COR2ED brings you Independent Medical Education from OBSTETRICS & GYNECOLOGY CONNECT, experts in obstetrics & gynecology https://t.co/ggOUJv0i5c
Joined November 2022
📢 Come and visit us in Berlin at #ESMO25! We'll be at Booth 4025 offering FREE profile headshots from our professional photographer & showcasing our range of high-quality Independent #MedicalEducation programmes across multiple therapy areas. See you there! #IME #MedTwitter
0
12
14
Dr. Sara Tolaney shares step-by-step clinical guidance on managing adverse events related to antibody–drug conjugates (ADCs) in HER2+ metastatic breast cancer. Watch this @BreastCaConnect video summary for practical strategies in #PatientManagement. #MedEd #Oncology
🔎 Managing AEs related to ADCs in HER2+ mBC T-DXd is a highly emetogenic agent. ➡️ Prophylaxis = 3-drug regimen: a 5-HT3 receptor antagonist, NK1 receptor antagonist + dexamethasone ➡️ A 4-drug regimen inc. olanzapine if prior 3-drug prophylaxis was inadequate Watch the
0
0
0
Watch the on-demand webinar with Profs. Fernando López-Ríos, @ChristianRolfo & Charlie Gourley on HER2 testing and the evolving role of IHC in lung & ovarian cancers. Access: ✅ Highlights ✅ Full webinar ✅ CME e-learning ✅ Downloadable resources 👉
1
0
0
Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life https://t.co/wgv6lgLXpp This narrative review explores the often-overlooked issue of treatment burden and its impact on quality of life
1
10
19
Advanced or recurrent endometrial cancer: Molecular classification & treatment decisions Medical experts Prof. @xmatiasguiu & Dr Jurjees Hasan explain the impact of molecular subtypes in treatment decisions in this video podcast 📺 Watch the video below Listen on all podcast
1
4
25
🧬 What do HCPs need to know about current treatment options for advanced/recurrent EndometrialCancer? An animated MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to
0
10
63
🎉 COR2ED has over 12k subscribers on YouTube! 🎉 Do you follow us? ▶️ https://t.co/6LLD7G78rT Join over 12k HCPs on our YouTube channel and stay up to date with #MedEd videos as they’re released 🎓 #MedicalEducation #Oncology #OBGYN
0
0
0
➡️Advanced #endometrialcarcinoma video podcast Prof. @xmatiasguiu & Dr Jurjees Hasan discuss: - Molecular classification & treatment decisions - Trial data - Shared decision-making 📺 Watch the video below Listen on all podcast platforms / get the transcript 👉
1
0
2
Catch this ESMO Virtual Plenary 2025 update on the latest TROPION-Breast01 study with Prof. François-Clément Bidard & Dr @BarbaraPistill2 This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated, inoperable or metastatic HR+/HER2– breast
➡️ Did TROPION-Breast01 final OS results reach statistical significance? ➡️ What do the data show about how Dato-DXd compares with chemotherapy? Get the answers from Prof. François-Clément Bidard & Dr @BarbaraPistill2 in this ESMO Virtual Plenary 2025 update 👇
0
0
1
🧬 What do HCPs need to know about current treatment options for advanced/recurrent #EndometrialCancer? An animated #MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to
1
16
105
Join Leading Experts & @COR2EDMedEd for Rapid Video Insights on Groundbreaking Data out of #ASCO25 LINK: https://t.co/7O0D3qP3WQ a series of brief videos featuring Prof. Gerhardt Attard presenting late-breaking prostate cancer trial results from the AMPLITUDE study, Prof.
1
15
18
Catch up on highlights from #ASCO25! Experts joined us at ASCO to share their insights on how the latest data could change clinical practice ➡️ Prof. @MarkSocinski: #NSCLC (downloadable slides also available) ➡️ Dr @AttardLab: #ProstateCancer ➡️ Dr @LizzySmyth1: #GastricCancer
0
0
0
Many women with postpartum haemorrhage (PPH) have no identifiable risk factors. Each year, 14 million women experience PPH, leading to 70,000 maternal deaths worldwide. Drs. Ahmadzia and Zdanowicz discuss how to ensure rapid access to treatment and support for your patients in
0
2
1
We are proud to collaborate with ICAN (@WarOnCancer), a patient advocacy group that focuses on personalised cancer care programmes, health IT, legislation, and research. Learn more here: https://t.co/nvYQ5z7KuJ Find many of our ICAN-endorsed programmes here:
0
0
0
Join Leading Experts & @COR2EDMedEd for Rapid Video Insights on Groundbreaking Data out of #ASCO25 LINK: https://t.co/7O0D3qP3WQ a series of brief videos featuring Prof. Gerhardt Attard presenting late-breaking prostate cancer trial results from the AMPLITUDE study, Prof.
0
13
14
Join Leading Experts & @COR2EDMedEd for Rapid Video Insights on Groundbreaking Data out of #ASCO25 LINK: https://t.co/7O0D3qP3WQ Coming soon: a series of brief videos featuring Prof. Gerhardt Attard presenting late-breaking prostate cancer trial results from the AMPLITUDE
0
11
13
🔎 In #EndometrialCancer, molecular classification is crucial not only for prognosis but also for guiding personalised treatment decisions Prof. @xmatiasguiu & Dr Jurjees Hasan explain more in this video podcast 📺 Listen on Apple/Spotify 👉 https://t.co/qtER75Uy5i This
0
0
0